Literature DB >> 6095893

Inhibition of angiotensin converting enzyme: mechanism and substrate dependence.

R Shapiro, J F Riordan.   

Abstract

The interaction of angiotensin converting enzyme with six metal-coordinating [(D-3-mercapto-2-methylpropanoyl)-L-Pro (captopril), N-[1(S)-carboxy-3-phenylpropyl]-L-Ala-L-Pro (MK-422), N-(phenylphosphoryl)-L-Phe-L-Phe, N alpha-(3-mercaptopropanoyl)-L-Arg, N alpha-[1(S)-carboxy-3-phenylpropyl]-Ala-L-Lys, and N-[1(S)-carboxy-5-aminopentyl]-L-Phe-Gly] and three dipeptide inhibitors (Gly-L-Trp, L-Phe-L-Arg, and L-Ala-L-Pro) was examined at pH 7.5 in the presence of 300 mM NaCl. Inhibition modes, apparent Ki [Ki(app)] values, and shapes of 1/v vs. [I] plots were found to vary with the substrate employed. All inhibitors except Phe-Arg were competitive with the substrate furanacryloyl (Fa)-Phe-Gly-Gly, while five of seven tested with Fa-Phe-Phe-Arg as substrate produced mixed patterns. Ki-(app) values for N-[1(S)-carboxy-5-aminopentyl]-L-Phe-Gly, N-(phenylphosphoryl)-L-Phe-L-Phe, Gly-Trp, and MK-422 were 8.3-, 5.5-, 4.7-, and 2.6-fold lower, respectively, when Fa-Phe-Gly-Gly was substrate, compared with values measured with Fa-Phe-Phe-Arg. In contrast, Ki(app) values for Phe-Arg and (3-mercaptopropanoyl)-Arg were lower (2.8- and 2.2-fold, respectively) when Fa-Phe-Phe-Arg was the substrate. Plots of 1/v vs. [I] for most of the inhibitors were nonlinear, to an extent which was also substrate dependent.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6095893     DOI: 10.1021/bi00317a021

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  Phosphonium compounds as new and specific inhibitors of bovine serum amine oxidase.

Authors:  Maria Luisa Di Paolo; Michele Lunelli; Marina Scarpa; Adelio Rigo
Journal:  Biochem J       Date:  2004-12-15       Impact factor: 3.857

Review 2.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

3.  Effect of temperature and chloride on steady-state inhibition of angiotensin I-converting enzyme by enalaprilat and ramiprilat.

Authors:  A Skoglof; P O Göthe; J Deinum
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

Review 4.  Perindopril. A review of its pharmacokinetics and clinical pharmacology.

Authors:  R J Macfadyen; K R Lees; J L Reid
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 5.  Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

6.  Polymorphic inhibition of human angiotensin I-converting enzyme by enalaprilat.

Authors:  E J Lee
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

7.  Binding to thermolysin of phenolate-containing inhibitors necessitates a revised mechanism of catalysis.

Authors:  W L Mock; M Aksamawati
Journal:  Biochem J       Date:  1994-08-15       Impact factor: 3.857

8.  Computer-aided lead optimization: improved small-molecule inhibitor of the zinc endopeptidase of botulinum neurotoxin serotype A.

Authors:  Jing Tang; Jewn Giew Park; Charles B Millard; James J Schmidt; Yuan-Ping Pang
Journal:  PLoS One       Date:  2007-08-22       Impact factor: 3.240

Review 9.  ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.

Authors:  Lizelle Lubbe; Gyles E Cozier; Delia Oosthuizen; K Ravi Acharya; Edward D Sturrock
Journal:  Clin Sci (Lond)       Date:  2020-11-13       Impact factor: 6.124

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.